Latest news

View all
14 EUR
/month

Read the latest issue of our magazine!

Read the latest issue of our magazine!

  • Beacons of life science: Learn more about Science for Good in the USA, popular science writer Julia Ravanis, and the many dedicated women working to increase female representation in leadership.
  • Cutting-edge science: Learn more about two groundbreaking clinical approaches marking a Nordic entry into the frontline of both diabetes and vision restoration.
  • Global report: Flanders’ economy is anchored by advanced manufacturing, logistics, and a life science sector that consistently performs far above the region’s size.
  • In addition: Stay updated on the latest news within women’s health, health tech, and AI, and find out what it’s like to be a PhD student in the life science industry.
Subscribe now

Opinion & debate

Clinical Trials

Clinical Trials – February 10, 2026

Lundbeck presents real-world data highlighting improvements in migraine

The company has announced six-month data from the 12-month, real-world INFUSE study, evaluating the effectiveness of Vyepti in adults with migraine who had failed at least one preventive anti-calcitonin gene–related peptide (aCGRP) treatment, at any time point previously.

Clinical Trials – February 2, 2026

SynAct Pharma initiates Phase 2 study in respiratory insufficiency

SynAct Pharma has initiated a Phase 2 study (RESPIRE) with resomelagon in patients hospitalized with respiratory insufficiency due to viral infections.

Clinical Trials – January 27, 2026

Takeda’s zasocitinib meets primary and secondary endpoints in Phase 3 study

The results showed that approximately 30 percent of patients achieved complete skin clearance (PASI 100) at week 16, and that more than half reached almost complete clearance (PASI 90).

Clinical Trials – January 27, 2026

DexTech Medical’s myeloma study, completed at the end of February

The results show that all patients responded positively to the ODX treatment, with a transition from progressive disease to stable disease.

Clinical Trials – January 12, 2026

Elicera Therapeutics announces final data from its Phase I/IIa trial

Elicera Therapeutics has announced final data from its Phase I/IIa clinical trial evaluating the oncolytic virus ELC-100 in patients with advanced, end-stage neuroendocrine tumors who had exhausted all currently available therapeutic options and having progressing diseases.

Clinical Trials – January 9, 2026

Sobi to advance Gamifant in interferon-gamma-driven sepsis

Sobi has announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (IDS), showed proof-of-concept with observed improvement in organ dysfunction and survival.

Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

NLS Insight

Global report – May 26, 2025

Doing business in the world’s new life science powerhouse

In a sector long dominated by the US and Europe, Mainland China is now catching up in global pharma and biotechnology. 

Nobel Prize Laureate – December 20, 2018

Frances H. Arnold: Better than Nature herself

Read Chris Tachibana’s exclusive interview with Frances H. Arnold, a Nobel Laureate in Chemistry 2018, and learn more about her bold approaches to optimizing enzymes for society’s benefit.

Sponsored content

Why Pharma Stays the Course on Emissions Reduction

While 2025 has seen many industries quietly scale back their climate commitments, pharma seems to take the opposite path. 

Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

Explore topics

Upcoming events

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.